Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

A disease focus

"ALS/MND is a truly devastating disease. At the UK DRI, we are committed to finding new treatments and changing the lives of those affected now and in the future." Prof Bart De Strooper
UK DRI Director

1. Background

Amyotrophic Lateral Sclerosis (ALS), or Motor Neurone Disease (MND), is a fatal neurodegenerative condition that causes progressive weakness of the muscles due to the degeneration of motor neurones in the brain and spinal cord. The average age at onset is 60 years and death usually occurs three years after the first symptoms appear, due to respiratory failure. Although there are some treatments available that can slow the progression by a few months, those affected are in desperate need of more effective therapeutics that improve symptoms and extend life expectancy.

2. UK DRI priority

UK DRI is the country's leading research institute for neurodegenerative disease with world experts across the ALS/MND research spectrum. Discovery science is the engine that drives medical progress; translational research is the process by which we apply our basic science discoveries to the needs of patients; clinical research is how we test these approaches in patients.

3. Meet the team

Adrian Isaacs3

Adrian Isaacs

  • UK DRI Group Leader
  • Frontotemporal dementia and amyotrophic lateral sclerosis disease mechanisms
  • UCL, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Bhuvaneish Selveraj Web 2

Bhuvaneish Selvaraj

  • UK DRI Emerging Leader
  • Mechanisms of selective vulnerability of motor neurons in amyotrophic lateral sclerosis
  • Edinburgh, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Chris Shaw

Chris Shaw

  • UK DRI Group Leader
  • Proteostatic mechanisms in FTD and ALS
  • King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Gabriel Balmus2

Gabriel Balmus

  • UK DRI Group Leader
  • Identifying neuroprotective mechanisms against genomic instability accrual in ageing and neurodegeneration
  • Cambridge, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Giampietro Schiavo

Giampietro Schiavo

  • UK DRI Group Leader
  • Restoring axonal transport deficits as a therapeutic strategy for neurodegenerative diseases
  • UCL, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Jernej Ule 1

Jernej Ule

  • UK DRI Centre Director
  • RNA networks in ALS/FTD
  • King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Marc David Ruepp

Marc-David Ruepp

  • UK DRI Group Leader
  • Altered RNA metabolism in neurodegeneration
  • King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Sarah Mizielinska

Sarah Mizielinska

  • UK DRI Group Leader
  • Single molecule nucleocytoplasmic transport dynamics in FTD/ALS
  • King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more
Siddharthan Chandran

Siddharthan Chandran

  • UK DRI Group Leader
  • Dissecting macroglial-neuronal crosstalk in C9ORF72 FTD/ALS
  • Edinburgh, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI
Read more

Founding funders

Latest tweets from @UKDRI

RT @suvankarpal: Congratulations to the formidable @drarpan100 for winning the ECR platform presentation prize at the #CUREND clinical work…
03 Feb 2023 17:11

RT @DrArpan100: Absolutely super, comprehensive talk by @DrNatalieRyan @drcionucl @UKDRI on her research into familial Alzheimer's dementia…
03 Feb 2023 12:09